Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terumo ( (JP:4543) ) just unveiled an update.
Terumo Corporation has announced its acquisition of OrganOx Limited for approximately USD 1.5 billion, marking its strategic entry into the organ transplantation sector. This move is expected to enhance Terumo’s business portfolio and address significant unmet medical needs by improving organ preservation and utilization rates, ultimately benefiting transplant patients and healthcare providers globally.
The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3165.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.
More about Terumo
Terumo Corporation is a Tokyo-based company specializing in the design and manufacturing of medical devices and equipment. The company is making a strategic entry into the organ transplantation-related sector by acquiring OrganOx Limited, a leader in organ preservation devices. Terumo aims to leverage its expertise to deliver innovative solutions in the field of organ transplantation.
YTD Price Performance: -10.15%
Average Trading Volume: 3,680,484
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen4046.2B
For a thorough assessment of 4543 stock, go to TipRanks’ Stock Analysis page.